Acumen Pharmaceuticals, Inc.
ABOS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001576885
No open-market purchases or sales by Acumen Pharmaceuticals, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $127.8M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Acumen Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 53 | 66 | +13 |
| Shares | 26.3M | 43.2M | +16.9M (+64.0%) |
| Value | $126.6M | $179.2M | +$52.6M (+41.5%) |
New holders (25)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (12)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| WMS Partners, LLC | 98,301 | $472.8K |
| J. Goldman & Co LP | 62,986 | $303.0K |
| D. E. Shaw & Co., Inc. | 60,504 | $291.0K |
| Group One Trading, L.P. | 32,800 | $157.8K |
| Prelude Capital Management, LLC | 31,100 | $149.6K |
| Balyasny Asset Management LLC | 30,222 | $145.4K |
| LMR Partners LLP | 14,663 | $70.5K |
| Cubist Systematic Strategies, LLC | 13,116 | $63.1K |
| Belvedere Trading LLC | 12,931 | $62.2K |
| BIT Capital GmbH | 11,618 | $55.9K |
| Squarepoint Ops LLC | 10,445 | $50.2K |
| Federation des caisses Desjardins du Quebec | 892 | $4.29K |